These approvals are based on positive outcomes from phase three trials, namely OlympiAD and EMBRACA [1, 11, 12]. The phase three OlympiAD trial aimed to assess the efficacy of olaparib versus standard chemotherapy (TPC) for treating HER2-negative metastatic BC patients who possessed a germline BRCA mutation. This evidence concerns the gene ERBB2 and breast cancer.